1. Inhibition of APE1 Expression Enhances the Antitumor Activity of Olaparib in Triple-Negative Breast Cancer
   Dan Jian et al, 2022, Evidence-Based Complementary and Alternative Medicine CrossRef
2. Contribution of BRCA1 5382insC mutation to triplene-gative and luminal types of breast cancer in Ukraine
   Anastasiia Samusieva et al, 2022, Breast Cancer Res Treat CrossRef
3. A global perspective on the ethnic-specific BRCA variation and its implication in clinical application
   San Ming Wang, 2022, Journal of the National Cancer Center CrossRef
4. Clinical significance of germline breast cancer susceptibility gene (gBRCA) testing and olaparib as maintenance therapy for patients with pancreatic cancer
   Yasuharu Kawamoto et al, 2024, BMC Cancer CrossRef
5. The Importance of Suppressing Pathological Periostin Splicing Variants with Exon 17 in Both Stroma and Cancer
   Kana Shibata et al, 2024, Cells CrossRef
6. Potential Therapeutic Targets in Triple‐Negative Breast Cancer Based on Gene Regulatory Network Analysis: A Comprehensive Systems Biology Approach
   Maryam Ahmadi et al, 2024, International Journal of Breast Cancer CrossRef
7. Prevalence of Germline BRCA1/2 Pathogenic Variants in Japanese Patients with Triple Negative Breast Cancer: A Single Center Retrospective Study
   Yuichi Ueda et al, 2024, Journal of Nihon University Medical Association CrossRef
8. Pancreatic cancer in a breast cancer patient with a germline BRCA2 pathogenic variant: A case report
   Hiroyasu Yamashiro et al, 2024, Tenri Med Bull CrossRef